Lohr et al., 2003 - Google Patents
Experimental treatment of pancreatic cancerLohr et al., 2003
- Document ID
- 4403606302957747078
- Author
- Lohr M
- Hummel F
- Gunzburg W
- Salmons B
- Publication year
- Publication venue
- FALK SYMPOSIUM
External Links
Snippet
Current treatment of ductal adenocarcinoma of the pancreas results in response rates around 15% with the quasi-standard gemcitabine¹. Combinations of known (5-fluorouracil (5- FU), gemcitabine, platin) and novel cytotoxic compounds (capecitabine, irinotecan, taxotere) …
- 208000008443 pancreatic carcinoma 0 title abstract description 52
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2435586C2 (en) | Cancer treatment with application of viruses fluoropyrimidines and camptothecins | |
| JPH05246895A (en) | Destruction of neoplastic cells targeted by the virus | |
| Ganly et al. | Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects | |
| WO2021154976A1 (en) | Methods of treating brain cancer with panobinostat | |
| ES2908854T3 (en) | Method for producing an antitumor arenavirus as well as arenavirus mutants | |
| Raraty et al. | New techniques and agents in the adjuvant therapy of pancreatic cancer | |
| Löhr et al. | Novel treatments and therapies in development for pancreatic cancer | |
| EP3402468A1 (en) | Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer | |
| WO2022115767A1 (en) | Methods of treating cancer | |
| CN116761883A (en) | Armed Seneca Valley Virus Oncolytic Therapeutic Compositions and Methods | |
| JP4423508B2 (en) | Cancer gene therapy drug | |
| Lohr et al. | Experimental treatment of pancreatic cancer | |
| US12059434B2 (en) | Short-term activated DC1s and methods for their production and use | |
| AU2019464086A1 (en) | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients | |
| EP4378473A1 (en) | Her2 vaccine composition | |
| JP6650953B2 (en) | Enhanced therapeutic use of purine nucleoside phosphorylase or nucleoside hydrolase in prodrug-related applications | |
| Schmidt-Wolf et al. | Gene therapy for hematological malignancies | |
| JP2020530485A (en) | Pharmaceutical kit and how to use it | |
| US20240366696A1 (en) | Using reprogrammed, personalized cancer stem cells as a triple-killer cancer treatment | |
| WO2024120489A1 (en) | Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug | |
| Peethambaram et al. | Second-line and subsequent therapy for ovarian carcinoma | |
| Du | Molecule-Targeted Drugs That Treat Colorectal Cancer | |
| Brinkman | Combining biomaterials and immunotherapeutic mRNA to combat cancer | |
| Foloppe et al. | TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma | |
| US20210106649A1 (en) | Synergistic combination of chemotherapy and peptide for treating cancer |